Health Condition 1: N189- Chronic kidney disease, unspecified
Conditions
Interventions
Intervention1: Nil: Nil
Control Intervention1: Nil: Nil
Sponsors
Fourrts India Laboratories Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male or female patients more than and equal to 18 years of age 2. Diagnosis of stage 1, stage 2, or stage 3 chronic kidney disease (CKD) as per the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) 3. Diagnosis of type 2 diabetes mellitus (T2DM) and/or hypertension (HTN) by the treating cardiologist 4. Patients on standard of care with or without N-acetylcysteine (NAC; 150 mg) and taurine (500 mg), as prescribed by the treating cardiologist 5. Patients with available data on uACR, serum creatinine, and eGFR as part of routine clinical practice at least at baseline and after 12+2 weeks of treatment
Exclusion criteria
Exclusion criteria: 1. Incomplete medical records with respect to the required study parameters
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Change in eGFR from baseline to 12+2 weeks of treatmentTimepoint: Baseline, 12?2 weeks;Proportion of patients with adverse events (AEs) and serious AEs (SAEs)Timepoint: Baseline to 12?2 weeks of treatment | — |
Primary
| Measure | Time frame |
|---|---|
| 1. Change in urinary albumin to creatinine ratio (uACR) from baseline to 12?2 weeks of treatment 2. Change in serum creatinine levels from baseline to 12?2 weeks of treatmentTimepoint: 1. Baseline to 12?2 weeks of treatment 2. Baseline to 12?2 weeks of treatment | — |
Countries
India
Contacts
Public ContactDr Monjori Mitra
Medclin Research Pvt Ltd
Outcome results
None listed